Skip to Content

At 1800Oncologist we believe that:

  • Patient education empowers action;
  • Patients should be armed with important facts about cancer prevention;
  • Patients should understand healthy lifestyles that reduce their cancer risks.

But, when there is a need for cancer care:

  • We provide patient-friendly information that engages patients in the cancer conversation;
  • We feature best-in-class videos in our interactive cancer education centers;
  • We support their role as active participants in the shared decision-making process.

Our editorial team and expert network create original, action-oriented content that incorporates insights about practical issues, enabling patients to more effectively communicate with their doctors and make informed decisions about their care.

1-800-Oncologist’s toll-free voice portal enables individuals to easily speak directly with a quality cancer treatment center or talk with a medication information specialist. Simply call 1-800-Oncologist (1-800-662-6564) to book an appointment with an oncologist or find the right medication information today.

1-800-Oncologist is the leading digital publisher of timely, easy-to-understand cancer information that patients can relate to, from breaking news and cancer features to treatment updates and medication

 

Latest Info Center

News

  • Blood Fats May Raise Prostate Cancer Risk
    Prostate cancer is one of the most common cancers in men, and high cholesterol may promote its growth. Even post-surgery, men with elevated blood fats may face an increased risk of recurrence.
  • Most Breast Cancer Patients Happy with Choice to Remove Non-Cancerous Breast
    Many women choose to remove the second, non-cancerous breast after a diagnosis. This preventive decision, though difficult, can offer peace of mind and potentially reduce future risk.
  • Mental Health Issues in Cancer Patients Differ by Cancer Type
    The struggle with cancer can extend beyond the physical. Some cancer types impose a more substantial mental burden on patients, affecting their emotional well-being during treatment.

Features

  • Black Men With Prostate Cancer May Need Different Approach
    Some men with prostate cancer are closely monitored without immediate treatment. However, this method may not be the most effective for Black men, who may benefit from alternative strategies.
  • ‘Angelina Effect’ May Have Boosted Screening for Breast Cancer
    A surge in genetic screenings in the UK has been observed, potentially influenced by celebrity endorsements, underscoring the impact of public figures on health decisions.
  • Fashion Changes May Explain Increase in Serious Skin Cancer
    Evolving beauty standards, from porcelain skin in the early 1900s to today’s tan trends, may partly explain the rising cases of serious skin cancers, highlighting the long-term impact of fashion on health.

FDA Alerts

  • FDA Approves New Rx to Control Chemo Side Effects
    The FDA has approved Akynzeo, a new oral medication designed to alleviate side effects associated with chemotherapy, offering patients better comfort during their cancer treatments.

Releases

  • Standard Medication for HER-2 Breast Cancer Remains Top Treatment
    While new treatments continue to emerge, the established standard therapy remains the primary choice for managing HER-2 positive breast cancer, due to its proven effectiveness.

Videos

  • E-Cigarettes May Not Help Cancer Patients Quit
    Many cancer patients turn to e-cigarettes to quit smoking, but a new study suggests these devices may not be as effective in curbing the habit as hoped.

All

  • Knowing Cancer Risk May Not Increase Screening Adherence
    Colorectal cancer (CRC) remains a leading cause of cancer death in the US. Even among high-risk individuals, adherence to routine screenings is often lower than recommended, despite awareness.

 

Medication Centers

Actiq

  • Type: Opioid Pain Medication
  • Uses: Primarily used to manage breakthrough cancer pain in patients who are already tolerant to other opioid painkillers.
  • Mechanism: Contains fentanyl, a powerful synthetic opioid, which acts on the brain to alter pain perception.
  • Administration: Available in lozenge form, which dissolves in the mouth for quick absorption.

Adrucil (Fluorouracil)

  • Type: Chemotherapy Agent
  • Uses: Commonly used in the treatment of colorectal, breast, stomach, and pancreatic cancers.
  • Mechanism: Adrucil is an antimetabolite, disrupting cancer cell replication by interfering with DNA and RNA synthesis.
  • Administration: Given via injection directly into a vein, typically as part of combination chemotherapy.

Arimidex (Anastrozole)

  • Type: Aromatase Inhibitor
  • Uses: Prescribed for hormone receptor-positive breast cancer in postmenopausal women.
  • Mechanism: Lowers estrogen levels by inhibiting the enzyme aromatase, reducing cancer cell growth fueled by estrogen.
  • Administration: Taken orally, typically once daily.

Avodart (Dutasteride)

  • Type: 5-Alpha Reductase Inhibitor
  • Uses: Primarily prescribed for benign prostatic hyperplasia (BPH) to reduce symptoms like difficulty urinating.
  • Mechanism: Blocks the conversion of testosterone to dihydrotestosterone (DHT), which is responsible for prostate growth.
  • Administration: Available in capsule form, usually taken once a day.

Casodex (Bicalutamide)

  • Type: Anti-Androgen
  • Uses: Used in combination with other treatments for prostate cancer.
  • Mechanism: Blocks androgen receptors, preventing androgens from stimulating prostate cancer cell growth.
  • Administration: Oral tablet taken once daily, often alongside other therapies.

Fentora

  • Type: Opioid Pain Medication
  • Uses: Prescribed for managing breakthrough pain in cancer patients already on long-term opioid therapy.
  • Mechanism: Like Actiq, it contains fentanyl, providing rapid pain relief through buccal (cheek) absorption.
  • Administration: Buccal tablet, designed to dissolve in the cheek for quick action.

Gleevec (Imatinib)

  • Type: Tyrosine Kinase Inhibitor
  • Uses: Treats various cancers, including chronic myeloid leukemia (CML) and gastrointestinal stromal tumors (GIST).
  • Mechanism: Blocks proteins that stimulate cancer cell growth by inhibiting specific tyrosine kinases.
  • Administration: Oral tablet, taken daily based on the prescribed dose and condition being treated.

Herceptin (Trastuzumab)

  • Type: Monoclonal Antibody
  • Uses: Targets HER2-positive breast and stomach cancers.
  • Mechanism: Binds to the HER2 receptor on cancer cells, blocking signals that promote cell growth.
  • Administration: Given as an intravenous (IV) infusion, typically in a clinical setting.

Procrit (Epoetin Alfa)

  • Type: Erythropoiesis-Stimulating Agent (ESA)
  • Uses: Used to treat anemia in cancer patients undergoing chemotherapy.
  • Mechanism: Stimulates the production of red blood cells by mimicking erythropoietin, a hormone produced by the kidneys.
  • Administration: Administered via injection under the skin or into a vein.

Tamoxifen

  • Type: Selective Estrogen Receptor Modulator (SERM)
  • Uses: Commonly used in hormone receptor-positive breast cancer in both premenopausal and postmenopausal women.
  • Mechanism: Blocks estrogen receptors in breast tissue, preventing estrogen from binding and promoting cancer cell growth.
  • Administration: Oral tablet, usually taken once daily.

Vinblastine

  • Type: Vinca Alkaloid Chemotherapy
  • Uses: Treats various cancers, including lymphoma, testicular cancer, and certain types of lung cancer.
  • Mechanism: Inhibits mitosis by binding to tubulin, preventing cell division in rapidly growing cancer cells.
  • Administration: Given as an intravenous injection, often in combination with other chemotherapy agents.

Vincasar PFS (Vincristine)

  • Type: Vinca Alkaloid Chemotherapy
  • Uses: Used in treating leukemia, lymphoma, and other cancers.
  • Mechanism: Disrupts microtubule formation, stopping cancer cells from dividing and growing.
  • Administration: Administered via intravenous injection, usually as part of a combination therapy.

Xeloda (Capecitabine)

  • Type: Antimetabolite Chemotherapy
  • Uses: Treats colorectal and breast cancers, often in combination with other therapies.
  • Mechanism: Capecitabine is converted into 5-FU in the body, targeting cancer cells by interfering with DNA synthesis.
  • Administration: Oral tablet, with dosage cycles based on cancer type and treatment plan.

Each medication entry’s image can be hyperlinked to more detailed product pages. This layout provides a clear, visually engaging experience for users exploring the Medication Centers section.



Roadmap to Reduce the Costs of Cancer Care in the State of Texas by $100 Million per Year

What’s the plan?

To empower oncologists with the resources to deliver more effective patient care using multi-content, multi-channel digital patient education.Digital Education improves practice productivity and patient outcomes:Consistent delivery of messaging to patientsMore efficient communication means less time spent in doctor/patient visitsWell-informed patients can actively manage their own healthTogether, these changes in process and behavior, made possible with digital patient education, can reduce provider costs by 5%.Here’s the math:The Cost Today - The Texas Department of State Health Services (DSHS) has determined that the total cost of cancer care in the state of Texas for 2007 was approximately $21.9 billion.1The Opportunity - Roughly 1,000 oncologists practice in the state of Texas.  If 100 of these oncologists (only 10%) reduced the cost of cancer care delivery by 5%, Texans could save $105M annually. If all Texas oncologists embraced digital patient education, the cost savings could reach as high as $1.05B per year.Authored by: Donald Hackett and Alexander Cavalli, PhDCitations:1 Philips, B.U., et al. (2009, March). The cost of cancer in Texas 2007. Department of Preventive Medicine and Community Health. University of Texas Medical Branch at Galveston.References:“HHS Releases National Plan to Improve Health Literacy,” U.S. Department of Health & Human Services“Readmissions drop when pharmacists visit patients' homes,” FierceHealthPayer“NCHC Should Keep the Focus on Adherence to Medicines,” Phrma“Eliminating Waste in US Health Care,” JAMACenters for Disease Control and Prevention  

Collection and Use of Personal Information

We collect the following personal information from you

  • Contact Information such as name, email address, mailing address, phone number

We also collect the following information from you

  • Demographic information such as age, education, gender, interests and zip code

As is true of most Web sites, we automatically gather information about your computer such as your IP address, browser type, referring/exit pages, and operating system.

We use this information to

  • Assess the needs of your business to determine suitable products
  • Send you requested product or service information
  • Respond to customer service requests
  • Send you a newsletter
  • Respond to your questions and concerns
  • Improve our Web site and marketing efforts
  • Conduct research and analysis
  • Display content based upon your interests

Choice/Opt-Out

You may choose to stop receiving our newsletter or marketing emails by following the unsubscribe instructions included in these emails or you can contact us at info@patientconversation.com .

We enable you to create a profile, and share information such as messages, photos, and videos with others. Please note that we cannot control the actions of others with whom you may choose to share your pages and information.

Information Sharing

We will share your personal information with third parties only in the ways that are described in this privacy statement. We do not sell your personal information to third parties.

We may provide your personal information to companies that provide services to help us with our business activities such as shipping your order or offering customer service. These companies are authorized to use your personal information only as necessary to provide these services to us.

We may also disclose your personal information

  • as required by law such as to comply with a subpoena, or similar legal process
  • when we believe in good faith that disclosure is necessary to protect our rights, protect your safety or the safety of others, investigate fraud, or respond to a government request,
  • if Patient Conversation Media, Inc. is involved in a merger, acquisition, or sale of all or a portion of its assets, you will be notified via email and/or a prominent notice on our Web site of any change in ownership or uses of your personal information, as well as any choices you may have regarding your personal information,
  • to any other third party with your prior consent to do so.
  • We share your personal information with other companies so that they can market their products or services to you. If you do not want us to share your personal information with these companies, contact us at info@patientconversation.com .

Cookies and Other Tracking Technologies

We use another company to place cookies on your computer to collect non-personally identifiable information to compile aggregated statistics for us about visitors to our site.

Advertising

We partner with a third party ad network to either display advertising on our Web site or to manage our advertising on other sites. Our ad network partner uses cookies and Web beacons to collect non-personally identifiable information about your activities on this and other Web sites to provide you targeted advertising based upon your interests. If you wish to not have this information used to serve you targeted ads, you may opt-out of being served targeted ads by clicking here (link to NAI opt-out: http://www.networkadvertising.org/managing/opt_out.asp). Please note this does not opt you out of being served advertising. You will continue to receive generic ads.

Web beacons

Our Web pages may also contain electronic images known as Web beacons (sometimes called single-pixel gifs) that are set by our third party partners. Web beacons are used along with cookies enabling our partners to compile aggregated statistics to analyze how our site is used.

We use a third party to gather information about how you and others use our Web site. For example, we will know how many users access a specific page and which links they clicked on. We use this aggregated information to understand and optimize how our site is used.


 

 

Local Shared Objects - Flash Cookies

Third Parties, with whom we partner to provide certain features on our site or to display advertising based upon your Web browsing activity, use Flash cookies to collect and store information. Flash cookies are different from browser cookies because of the amount of, type of, and how data is stored. Cookie management tools provided by your browser will not remove Flash cookies. To learn how to manage privacy and storage settings for Flash cookies click here: http://www.macromedia.com/support/documentation/en/flashplayer/help/sett....

Links to Other Web Sites

Our Site includes links to other Web sites whose privacy practices may differ from those of Patient Conversation Media, Inc.. If you submit personal information to any of those sites, your information is governed by their privacy statements. We encourage you to carefully read the privacy statement of any Web site you visit.

Security

The security of your personal information is important to us. We follow generally accepted industry standards to protect the personal information submitted to us, both during transmission and once we receive it. No method of transmission over the Internet, or method of electronic storage, is 100% secure, however. Therefore, we cannot guarantee its absolute security.

If you have any questions about security on our Web site, you can contact us at info@patientconversation.com

Additional Policy Information

Correcting and Updating Your Personal Information

To review and update your personal information to ensure it is accurate, contact us at info@patientconversation.com.


Why Join the 1-800-Oncologist Network?

 

1-800-Oncologists's Pay-Per-Conversation™ advertising service offers the most effective way to reach prospective patients when they are ready to schedule an appointment--by speaking with them. Our Pay-Per-Conversation™ advertising enables you to expand your practice, one patient at a time.

No Risk

  • Only realize a fee after speaking with a prospective patient for 60 seconds or longer.   No long-term contracts or monthly minimums.  No gimmicks.  Just phone calls.

Self-qualified motivated callers

  • We connect you with prospective patients actively seeking treatment.

Measurable ROI

  • Easily calculate the return on your advertising investment with our call analytics reports

Flexibility

  • Customization of market reach while working within your advertising budget.

PPC Advertising Delivers Measurable Value

 

If you currently advertise on Google, Bing or Yahoo, 1-800-Oncologist's Pay-Per-Conversation™ advertising service is very similar. We deliver prospective patients, defined by your service area, patient demographics, and marketing budget.

However, 1-800-Oncologist delivers conversations with these qualified prospective patients directly to you, generating measurable, easy-to-understand results:

  • Trackable patient conversions: Our Pay-Per-Conversation™ advertising service enables health advertisers to know how many telephone calls turn into prospective patients.
  • Measurable value: While the value of 'a click to a web site’ remains an abstract metric, telephone conversations with prospective patients are easily tracked and valued. Measuring ROI is easily accomplished.

 

1-800-Oncologist Prescribe

 

Our 1-800-Oncologist Prescribe offering makes it easy interact with current and potential patients online.  Engage your patients across multiple points — in your practice and online — when and where it’s most impactful.

What is 1-800-Oncologist Prescribe?

Prescribe is a solutions suite that customizes and distributes easy-to-understand patient education at key touch points throughout the care delivery workflow:

  • In your waiting room or in eNewsletters—Print-ready education materials and custom content for newsletters
  • On your website—Active News™ condition-specific news feeds integrate directly with your website
  • Within your social networks—Social Stream™ delivers the latest health news to your social networks including Facebook, Twitter and Google+
  • After an appointment— Patient education content is codified for easily integration with EMR and eRx systems
  • On mobile devices — Mobile-friendly information delivered on-demand to Apple and Android smartphones and tablets

Consistent Patient Engagement

More effective patient-provider communication is a key component to more efficient care delivery, improved overall outcomes and increased patient satisfaction and loyalty.

Prescribe offers a patient-centric approach to care designed to reinforce patients’ understanding of important health information and increase patient involvement in the shared decision making process.

The Prescribe suite streamlines communication across print, online, social and mobile platforms, offering patients on-demand access to consistent information in a number of patient-friendly formats.

Our solutions integrate personalized patient education at the point of care and beyond to keep patients actively engaged in their health.

Why Prescribe?

  • Prescribe is completely FREE
  • 1-800-Oncologist does the heavy lifting, you enjoy the benefits
  • Custom content integrates your practice name and logo
  • Easy-to-understand, doctor-reviewed news and video
  • Build patient trust and loyalty with consistent digital conversations

1-800-Oncologist Prescribe™ Activation

Activation of 1-800-Oncologist Prescribe™ is quick, easy and free for providers! Providers simply select the content they would like to distribute from a wide range of health conditions and choose a content delivery package.

If you would like to learn more about 1-800-Oncologist Prescribe or are interested in signing up please contact info@1800Oncologist.com

Member Support Services

1-800-Oncologist is on call to support your practice. A representative from our Member Support Services team will be assigned to your practice to answer any questions and ensure that your activation is quick and simple.

If you have any questions about 1-800-Oncologist Prescribe™ please contact info@1800Oncologist.com